1. Home
  2. DCTH vs SENS Comparison

DCTH vs SENS Comparison

Compare DCTH & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$14.42

Market Cap

578.4M

Sector

Health Care

ML Signal

HOLD

Logo Senseonics Holdings Inc.

SENS

Senseonics Holdings Inc.

HOLD

Current Price

$7.51

Market Cap

476.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCTH
SENS
Founded
1988
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
578.4M
476.9M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
DCTH
SENS
Price
$14.42
$7.51
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
★ $24.00
$13.67
AVG Volume (30 Days)
251.9K
★ 559.3K
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 107.53
N/A
EPS
★ 0.04
N/A
Revenue
N/A
★ $16,389,000.00
Revenue This Year
$24.61
$82.21
Revenue Next Year
$24.27
$55.63
P/E Ratio
$368.38
★ N/A
Revenue Growth
N/A
★ 19.85
52 Week Low
$8.12
$4.79
52 Week High
$17.42
$10.64

Technical Indicators

Market Signals
Indicator
DCTH
SENS
Relative Strength Index (RSI) 39.08 34.74
Support Level $14.26 $7.35
Resistance Level $16.51 $7.57
Average True Range (ATR) 0.51 0.48
MACD -0.06 -0.21
Stochastic Oscillator 17.28 8.79

Price Performance

Historical Comparison
DCTH
SENS

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

About SENS Senseonics Holdings Inc.

Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.

Share on Social Networks: